Janpix

United States
Primghar, Iowa, United States, 02142

Company profile

Janpix company profile

Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and their relevance in certain cancers, in particular for STAT3 & STAT5, validated. Inhibiting the function of STAT proteins though has been very challenging thus far and Janpix developed new chemistry to address this complex problem.

Business identity

Operating status
Closed
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Postal code
02142
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
2
Total equity funding
$27.7M
Last funding
Series B / $10M / 2020-10-07
Last equity funding
Series B / $10M
Investors
1
Lead investors
1
Founders
2
Closed on
2021-03-14
Exited on
2021-01-23

Founders and investors

Founders

Patrick T. GunningPierre Cortes

Lead investors

Medicxi

Investors

Medicxi